AbbVie (ABBV) Announces Positive ABT-414 Phase 1 Data in Aggressive Brain Cancer
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 – an investigational antibody ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
